| ■ 영문 제목 : Global GERD Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR71291-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2022년 12월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (24시간 이내) ■ 조사대상 지역 : 북미, 유럽, 아시아, 기타 지역 ■ 산업 분야 : 의료 |
| Single User (1명 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| 테크나비오 조사회사의 시장 조사 보고서는 세계의 위식도 역류증 (GERD) 시장 규모가 2022년에서 2027년 사이에 908.49백만 달러에 달하며, 예측 기간 동안 연평균 3.4% 성장할 것으로 전망하고 있습니다. 본 조사 자료는 세계의 위식도 역류증 (GERD) 시장에 대해 조사하여, 개요, 시장 현황, 시장 규모 및 예측, 과거 시장 규모, 파이브 포스 분석, 투여 경로별 (경구제, 비경구제) 분석, 종류별 (제산제, PPI, H2 수용체 길항제, 운동 촉진약) 분석, 고객 현황, 지역별 (북미, 유럽, 아시아, 기타 지역, 미국, 독일, 영국, 중국, 캐나다) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 문서는 Bayer AG, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, iNova Pharmaceuticals, Johnson and Johnson, Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., The Procter and Gamble Co., Abbott Laboratories와 같은 기업 정보가 수록되어 있습니다. ・개요 ・시장 현황 ・시장 규모 및 예측 ・과거 시장 규모 ・파이브 포스 분석 ・세계의 위식도 역류증 (GERD) 시장 규모 : 투여 경로별 - 경구제의 시장 규모 - 비경구제의 시장 규모 ・세계의 위식도 역류증 (GERD) 시장 규모 : 종류별 - 제산제의 시장 규모 - PPI의 시장 규모 - H2 수용체 길항제의 시장 규모 - 운동 촉진약의 시장 규모 ・고객 현황 ・세계의 위식도 역류증 (GERD) 시장 규모 : 지역별 - 북미의 위식도 역류증 (GERD) 시장 - 유럽의 위식도 역류증 (GERD) 시장 - 아시아의 위식도 역류증 (GERD) 시장 - 기타 지역의 위식도 역류증 (GERD) 시장 - 미국의 위식도 역류증 (GERD) 시장 - 독일의 위식도 역류증 (GERD) 시장 - 영국의 위식도 역류증 (GERD) 시장 - 중국의 위식도 역류증 (GERD) 시장 - 캐나다의 위식도 역류증 (GERD) 시장 ・성장 요인/과제/동향 ・기업 현황 ・기업 분석 테크나비오사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 테크나비오사의 시장 조사 보고서는 정확한 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
Technavio는 2023-2027년 동안의 위식도 역류질환(GERD) 시장을 모니터링하고 있으며, 2022-2027년 동안 9억 849만 달러 성장할 것으로 예상하고 있으며, 이 기간 동안 연평균 성장률(CAGR)은 3.4%에 이를 것으로 보입니다. 이 보고서는 GERD 시장에 대한 전반적인 분석, 시장 규모 및 예측, 트렌드, 성장 동인 및 도전 과제, 약 25개 공급업체에 대한 분석을 제공합니다.
현재 시장 상황, 최신 트렌드 및 동인, 전반적인 시장 환경에 대한 최신 분석이 제공됩니다. 시장 성장의 주요 원인은 증가하는 노인 인구, 나쁜 생활 습관, 약물 및 건강 보조 식품의 과도한 사용입니다.
Technavio의 GERD 시장은 다음과 같이 분류됩니다.
투여 경로에 따른 분류:
– 경구 투여
– 주사 투여
약물 유형에 따른 분류:
– 제산제(antacid)
– 프로톤 펌프 억제제(PPI)
– H2 수용체 길항제
– 프로키네틱 약물
지역에 따른 분류:
– 북미
– 유럽
– 아시아
– 기타 지역(ROW)
이 연구는 비만의 증가하는 유병률이 향후 몇 년 동안 GERD 시장 성장의 주요 원인 중 하나로 작용할 것임을 확인합니다. 또한, 전자상거래 시장의 성장과 GERD에 대한 인식 증가는 시장에서 상당한 수요를 이끌어낼 것입니다.
Technavio는 여러 출처의 데이터를 연구, 종합 및 요약하여 시장을 상세히 분석합니다. 이 보고서는 GERD 시장의 규모, 예측, 산업 분석을 포함합니다.
Technavio의 강력한 공급업체 분석은 고객이 시장에서의 위치를 개선하는 데 도움을 주기 위해 설계되었습니다. 이 보고서는 Bayer AG, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Cipla Ltd., Dr Reddy’s Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, iNova Pharmaceuticals, Johnson and Johnson, Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., The Procter and Gamble Co., Abbott Laboratories 등 여러 주요 GERD 시장 공급업체에 대한 자세한 분석을 제공합니다. 또한, GERD 시장 분석 보고서에는 시장 성장에 영향을 미칠 향후 트렌드 및 도전에 대한 정보가 포함되어 있어 기업들이 모든 성장 기회를 전략적으로 활용하는 데 도움을 줍니다.
이 연구는 주요 산업 참가자들로부터의 정보와 더불어 1차 및 2차 정보를 객관적으로 조합하여 수행되었습니다. 이 보고서는 포괄적인 시장 및 공급업체 환경과 주요 공급업체 분석을 포함하고 있습니다.
Technavio는 수익, 가격, 경쟁 및 프로모션과 같은 주요 매개변수 분석을 통해 시장을 상세히 설명합니다. 또한, 주요 산업 인플루언서를 식별하여 다양한 시장 측면을 제시합니다. 제공된 데이터는 포괄적이며 신뢰할 수 있는 결과로, 광범위한 연구(1차 및 2차 연구)를 바탕으로 하고 있습니다. Technavio의 시장 조사 보고서는 완전한 경쟁 환경과 심층적인 공급업체 선택 방법론 및 분석을 제공하며, 정량적 및 정성적 연구를 통해 정확한 시장 성장을 예측합니다.
■ 보고서 목차• 1 요약 • 3 시장 규모 • 4 과거 시장 규모 o 표 47: 제산제 – 시장 규모 및 전망 차트(2022-2027, 백만 달러) o 표 49: 제산제 차트 – 2022-2027년 전년 대비 성장률(%) o 표 51: PPI 차트 – 2022-2027년 시장 규모 및 전망(백만 달러) o 9.2 지역별 비교 o 표 73: 유럽 시장 규모 및 전망 차트 2022-2027 (백만 달러) 첨부 자료: 표 1: 요약 – 시장 개요 차트 표 33: 투여 경로별 비교 데이터 표 첨부자료 131: 아우로빈도 파마(Aurobindo Pharma) 주식회사 – 주요 제품 및 서비스 첨부자료 152: 프레제니우스 SE & Co. KGaA – 주요 뉴스 첨부자료 169: 루핀(Lupin Ltd.) – 주요 뉴스 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market by Geography o Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration o Exhibit 06: Executive Summary - Chart on Market Segmentation by Type o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) • 4 Historic Market Size o 4.1 Global GERD market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on Global GERD market 2017 - 2021 ($ million) o 4.2 Route of Administration Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million) o 4.3 Drug Type Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Drug Type Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) • 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 • 6 Market Segmentation by Route of Administration o 6.1 Market segments o Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%) o Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%) o 6.2 Comparison by Route of Administration o Exhibit 32: Chart on Comparison by Route of Administration o Exhibit 33: Data Table on Comparison by Route of Administration o 6.3 Oral - Market size and forecast 2022-2027 o Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%) o 6.4 Parenteral - Market size and forecast 2022-2027 o Exhibit 38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Parenteral - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%) o 6.5 Market opportunity by Route of Administration o Exhibit 42: Market opportunity by Route of Administration ($ million) • 7 Market Segmentation by Type o 7.1 Market segments o Exhibit 43: Chart on Type - Market share 2022-2027 (%) o Exhibit 44: Data Table on Type - Market share 2022-2027 (%) o 7.2 Comparison by Type o Exhibit 45: Chart on Comparison by Type o Exhibit 46: Data Table on Comparison by Type o 7.3 Antacid - Market size and forecast 2022-2027 o Exhibit 47: Chart on Antacid - Market size and forecast 2022-2027 ($ million) o Exhibit 48: Data Table on Antacid - Market size and forecast 2022-2027 ($ million) o Exhibit 49: Chart on Antacid - Year-over-year growth 2022-2027 (%) o Exhibit 50: Data Table on Antacid - Year-over-year growth 2022-2027 (%) o 7.4 PPI - Market size and forecast 2022-2027 o Exhibit 51: Chart on PPI - Market size and forecast 2022-2027 ($ million) o Exhibit 52: Data Table on PPI - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Chart on PPI - Year-over-year growth 2022-2027 (%) o Exhibit 54: Data Table on PPI - Year-over-year growth 2022-2027 (%) o 7.5 H2 receptor antagonist drugs - Market size and forecast 2022-2027 o Exhibit 55: Chart on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 56: Data Table on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Chart on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%) o Exhibit 58: Data Table on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%) o 7.6 Pro-Kinetic drugs - Market size and forecast 2022-2027 o Exhibit 59: Chart on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 60: Data Table on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 61: Chart on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%) o Exhibit 62: Data Table on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%) o 7.7 Market opportunity by Type o Exhibit 63: Market opportunity by Type ($ million) • 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 65: Chart on Market share by geography 2022-2027 (%) o Exhibit 66: Data Table on Market share by geography 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 67: Chart on Geographic comparison o Exhibit 68: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 Germany - Market size and forecast 2022-2027 o Exhibit 89: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 90: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 91: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 92: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.9 UK - Market size and forecast 2022-2027 o Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.10 China - Market size and forecast 2022-2027 o Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million) o Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million) o Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%) o Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%) o 9.11 Canada - Market size and forecast 2022-2027 o Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity by geography o Exhibit 105: Market opportunity by geography ($ million) • 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 106: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends • 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 108: Overview on factors of disruption o 11.4 Industry risks o Exhibit 109: Impact of key risks on business • 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 110: Vendors covered o 12.2 Market positioning of vendors o Exhibit 111: Matrix on vendor position and classification o 12.3 Abbott Laboratories o Exhibit 112: Abbott Laboratories - Overview o Exhibit 113: Abbott Laboratories - Business segments o Exhibit 114: Abbott Laboratories - Key news o Exhibit 115: Abbott Laboratories - Key offerings o Exhibit 116: Abbott Laboratories - Segment focus o 12.4 Alkem Laboratories Ltd. o Exhibit 117: Alkem Laboratories Ltd. - Overview o Exhibit 118: Alkem Laboratories Ltd. - Business segments o Exhibit 119: Alkem Laboratories Ltd. - Key news o Exhibit 120: Alkem Laboratories Ltd. - Key offerings o Exhibit 121: Alkem Laboratories Ltd. - Segment focus o 12.5 Apotex Inc. o Exhibit 122: Apotex Inc. - Overview o Exhibit 123: Apotex Inc. - Product / Service o Exhibit 124: Apotex Inc. - Key offerings o 12.6 AstraZeneca Plc o Exhibit 125: AstraZeneca Plc - Overview o Exhibit 126: AstraZeneca Plc - Product / Service o Exhibit 127: AstraZeneca Plc - Key news o Exhibit 128: AstraZeneca Plc - Key offerings o 12.7 Aurobindo Pharma Ltd. o Exhibit 129: Aurobindo Pharma Ltd. - Overview o Exhibit 130: Aurobindo Pharma Ltd. - Product / Service o Exhibit 131: Aurobindo Pharma Ltd. - Key offerings o 12.8 Bayer AG o Exhibit 132: Bayer AG - Overview o Exhibit 133: Bayer AG - Business segments o Exhibit 134: Bayer AG - Key news o Exhibit 135: Bayer AG - Key offerings o Exhibit 136: Bayer AG - Segment focus o 12.9 Cipla Ltd. o Exhibit 137: Cipla Ltd. - Overview o Exhibit 138: Cipla Ltd. - Business segments o Exhibit 139: Cipla Ltd. - Key news o Exhibit 140: Cipla Ltd. - Key offerings o Exhibit 141: Cipla Ltd. - Segment focus o 12.10 Dr Reddys Laboratories Ltd. o Exhibit 142: Dr Reddys Laboratories Ltd. - Overview o Exhibit 143: Dr Reddys Laboratories Ltd. - Business segments o Exhibit 144: Dr Reddys Laboratories Ltd. - Key offerings o Exhibit 145: Dr Reddys Laboratories Ltd. - Segment focus o 12.11 Eisai Co. Ltd. o Exhibit 146: Eisai Co. Ltd. - Overview o Exhibit 147: Eisai Co. Ltd. - Business segments o Exhibit 148: Eisai Co. Ltd. - Key offerings o Exhibit 149: Eisai Co. Ltd. - Segment focus o 12.12 Fresenius SE and Co. KGaA o Exhibit 150: Fresenius SE and Co. KGaA - Overview o Exhibit 151: Fresenius SE and Co. KGaA - Business segments o Exhibit 152: Fresenius SE and Co. KGaA - Key news o Exhibit 153: Fresenius SE and Co. KGaA - Key offerings o Exhibit 154: Fresenius SE and Co. KGaA - Segment focus o 12.13 GlaxoSmithKline Plc o Exhibit 155: GlaxoSmithKline Plc - Overview o Exhibit 156: GlaxoSmithKline Plc - Business segments o Exhibit 157: GlaxoSmithKline Plc - Key offerings o Exhibit 158: GlaxoSmithKline Plc - Segment focus o 12.14 iNova Pharmaceuticals o Exhibit 159: iNova Pharmaceuticals - Overview o Exhibit 160: iNova Pharmaceuticals - Product / Service o Exhibit 161: iNova Pharmaceuticals - Key offerings o 12.15 Johnson and Johnson o Exhibit 162: Johnson and Johnson - Overview o Exhibit 163: Johnson and Johnson - Business segments o Exhibit 164: Johnson and Johnson - Key news o Exhibit 165: Johnson and Johnson - Key offerings o Exhibit 166: Johnson and Johnson - Segment focus o 12.16 Lupin Ltd. o Exhibit 167: Lupin Ltd. - Overview o Exhibit 168: Lupin Ltd. - Product / Service o Exhibit 169: Lupin Ltd. - Key news o Exhibit 170: Lupin Ltd. - Key offerings o 12.17 Perrigo Co. Plc o Exhibit 171: Perrigo Co. Plc - Overview o Exhibit 172: Perrigo Co. Plc - Business segments o Exhibit 173: Perrigo Co. Plc - Key news o Exhibit 174: Perrigo Co. Plc - Key offerings o Exhibit 175: Perrigo Co. Plc - Segment focus • 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 176: Inclusions checklist o Exhibit 177: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 178: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 179: Research methodology o Exhibit 180: Validation techniques employed for market sizing o Exhibit 181: Information sources o 13.5 List of abbreviations o Exhibit 182: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market by Geography Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration Exhibits6: Executive Summary - Chart on Market Segmentation by Type Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on Global GERD market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Drug Type Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Route of Administration - Market share 2022-2027 (%) Exhibits31: Data Table on Route of Administration - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Route of Administration Exhibits33: Data Table on Comparison by Route of Administration Exhibits34: Chart on Oral - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Oral - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Oral - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Oral - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Parenteral - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%) Exhibits42: Market opportunity by Route of Administration ($ million) Exhibits43: Chart on Type - Market share 2022-2027 (%) Exhibits44: Data Table on Type - Market share 2022-2027 (%) Exhibits45: Chart on Comparison by Type Exhibits46: Data Table on Comparison by Type Exhibits47: Chart on Antacid - Market size and forecast 2022-2027 ($ million) Exhibits48: Data Table on Antacid - Market size and forecast 2022-2027 ($ million) Exhibits49: Chart on Antacid - Year-over-year growth 2022-2027 (%) Exhibits50: Data Table on Antacid - Year-over-year growth 2022-2027 (%) Exhibits51: Chart on PPI - Market size and forecast 2022-2027 ($ million) Exhibits52: Data Table on PPI - Market size and forecast 2022-2027 ($ million) Exhibits53: Chart on PPI - Year-over-year growth 2022-2027 (%) Exhibits54: Data Table on PPI - Year-over-year growth 2022-2027 (%) Exhibits55: Chart on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million) Exhibits56: Data Table on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million) Exhibits57: Chart on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%) Exhibits58: Data Table on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%) Exhibits59: Chart on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million) Exhibits60: Data Table on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million) Exhibits61: Chart on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%) Exhibits62: Data Table on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%) Exhibits63: Market opportunity by Type ($ million) Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits65: Chart on Market share by geography 2022-2027 (%) Exhibits66: Data Table on Market share by geography 2022-2027 (%) Exhibits67: Chart on Geographic comparison Exhibits68: Data Table on Geographic comparison Exhibits69: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits70: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits71: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits72: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits73: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits75: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits76: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits77: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits78: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits79: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits80: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits85: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits86: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits87: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits88: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits89: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits90: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits91: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits92: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits93: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits94: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits95: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits96: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits97: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibits98: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibits99: Chart on China - Year-over-year growth 2022-2027 (%) Exhibits100: Data Table on China - Year-over-year growth 2022-2027 (%) Exhibits101: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits102: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits103: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits104: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits105: Market opportunity by geography ($ million) Exhibits106: Impact of drivers and challenges in 2022 and 2027 Exhibits107: Overview on Criticality of inputs and Factors of differentiation Exhibits108: Overview on factors of disruption Exhibits109: Impact of key risks on business Exhibits110: Vendors covered Exhibits111: Matrix on vendor position and classification Exhibits112: Abbott Laboratories - Overview Exhibits113: Abbott Laboratories - Business segments Exhibits114: Abbott Laboratories - Key news Exhibits115: Abbott Laboratories - Key offerings Exhibits116: Abbott Laboratories - Segment focus Exhibits117: Alkem Laboratories Ltd. - Overview Exhibits118: Alkem Laboratories Ltd. - Business segments Exhibits119: Alkem Laboratories Ltd. - Key news Exhibits120: Alkem Laboratories Ltd. - Key offerings Exhibits121: Alkem Laboratories Ltd. - Segment focus Exhibits122: Apotex Inc. - Overview Exhibits123: Apotex Inc. - Product / Service Exhibits124: Apotex Inc. - Key offerings Exhibits125: AstraZeneca Plc - Overview Exhibits126: AstraZeneca Plc - Product / Service Exhibits127: AstraZeneca Plc - Key news Exhibits128: AstraZeneca Plc - Key offerings Exhibits129: Aurobindo Pharma Ltd. - Overview Exhibits130: Aurobindo Pharma Ltd. - Product / Service Exhibits131: Aurobindo Pharma Ltd. - Key offerings Exhibits132: Bayer AG - Overview Exhibits133: Bayer AG - Business segments Exhibits134: Bayer AG - Key news Exhibits135: Bayer AG - Key offerings Exhibits136: Bayer AG - Segment focus Exhibits137: Cipla Ltd. - Overview Exhibits138: Cipla Ltd. - Business segments Exhibits139: Cipla Ltd. - Key news Exhibits140: Cipla Ltd. - Key offerings Exhibits141: Cipla Ltd. - Segment focus Exhibits142: Dr Reddys Laboratories Ltd. - Overview Exhibits143: Dr Reddys Laboratories Ltd. - Business segments Exhibits144: Dr Reddys Laboratories Ltd. - Key offerings Exhibits145: Dr Reddys Laboratories Ltd. - Segment focus Exhibits146: Eisai Co. Ltd. - Overview Exhibits147: Eisai Co. Ltd. - Business segments Exhibits148: Eisai Co. Ltd. - Key offerings Exhibits149: Eisai Co. Ltd. - Segment focus Exhibits150: Fresenius SE and Co. KGaA - Overview Exhibits151: Fresenius SE and Co. KGaA - Business segments Exhibits152: Fresenius SE and Co. KGaA - Key news Exhibits153: Fresenius SE and Co. KGaA - Key offerings Exhibits154: Fresenius SE and Co. KGaA - Segment focus Exhibits155: GlaxoSmithKline Plc - Overview Exhibits156: GlaxoSmithKline Plc - Business segments Exhibits157: GlaxoSmithKline Plc - Key offerings Exhibits158: GlaxoSmithKline Plc - Segment focus Exhibits159: iNova Pharmaceuticals - Overview Exhibits160: iNova Pharmaceuticals - Product / Service Exhibits161: iNova Pharmaceuticals - Key offerings Exhibits162: Johnson and Johnson - Overview Exhibits163: Johnson and Johnson - Business segments Exhibits164: Johnson and Johnson - Key news Exhibits165: Johnson and Johnson - Key offerings Exhibits166: Johnson and Johnson - Segment focus Exhibits167: Lupin Ltd. - Overview Exhibits168: Lupin Ltd. - Product / Service Exhibits169: Lupin Ltd. - Key news Exhibits170: Lupin Ltd. - Key offerings Exhibits171: Perrigo Co. Plc - Overview Exhibits172: Perrigo Co. Plc - Business segments Exhibits173: Perrigo Co. Plc - Key news Exhibits174: Perrigo Co. Plc - Key offerings Exhibits175: Perrigo Co. Plc - Segment focus Exhibits176: Inclusions checklist Exhibits177: Exclusions checklist Exhibits178: Currency conversion rates for US$ Exhibits179: Research methodology Exhibits180: Validation techniques employed for market sizing Exhibits181: Information sources Exhibits182: List of abbreviations |
| ※참고 정보 위식도 역류증(GERD, Gastroesophageal Reflux Disease)은 위 내용물이 식도로 역류하여 다양한 증상과 합병증을 유발하는 질환이다. 정상적으로 식도와 위 사이에는 하부식도괄약근(LES)이라는 근육이 있어 위의 내용물이 식도로 넘어가지 않도록 막아준다. 그러나 여러 가지 원인으로 이 괄약근이 약해지거나 기능 이상이 생기면 위산이나 위 내용물이 식도로 역류하게 된다. 이 과정에서 식도의 점막이 위산에 의해 자극받아 염증이 생기거나 통증을 유발하게 되며, 이로 인해 다양한 증상이 나타난다. GERD의 주요 증상으로는 가슴 쓰림(heartburn), 역류, 목의 이물감, 인후통, 기침, 쉰 목소리, 심한 경우에는 천식이나 후두염과 같은 호흡기 증상이 포함될 수 있다. 특히 가슴 쓰림은 가장 흔한 증상으로, 주로 식사 후 또는 누웠을 때 악화된다. 이러한 증상들은 일상 생활에 큰 지장을 초래할 수 있으며, 심각한 경우에는 식도염, 식도 협착, 바렛 식도와 같은 합병증을 유발할 수 있어 장기적인 관리와 치료가 필요하다. 위식도 역류증은 크게 두 가지로 나눌 수 있다. 첫 번째는 비정상적인 식도 역류로 인해 발생하는 일차성 GERD이며, 두 번째는 위장관의 구조적 이상이나 운동성 장애로 인해 발생하는 이차성 GERD이다. 일차성 GERD는 보통 비만, 흡연, 식습관, 스트레스 등과 관련이 있으며, 이차성 GERD는 식도 하부 괄약근의 해부학적 이상, 위장관의 신경 혹은 근육의 기능 장애 등에 기인한다. 위식도 역류증의 진단은 주로 환자의 증상과 병력에 기초하여 이루어지며, 필요에 따라 내시경 검사, 24시간 식도 pH 모니터링, 식도 운동 검사 등을 시행할 수 있다. 이러한 검사를 통해 식도의 염증 상태, 운동성, pH 변화를 확인함으로써 보다 정확한 진단을 내리고 효과적인 치료 방침을 세울 수 있다. GERD의 치료는 일반적으로 생활습관 변화, 약물 요법, 그리고 필요시 수술적 치료로 구분된다. 우선적으로 권장되는 생활습관 변화로는 체중 감소, 규칙적인 식사, 식사 후 일정 시간 지나서 눕기, 매운 음식이나 고지방 음식, 카페인, 알코올 등을 피하는 것이다. 이러한 변화를 통해 증상을 완화할 수 있는 경우가 많다. 약물 요법에는 위산 분비 억제제인 프로톤 펌프 억제제(PPI), H2 수용체 길항제, 제산제 등이 사용되며, 이는 위산의 분비를 줄여주거나 중화시켜서 증상을 개선하는 데 도움을 준다. 마지막으로, 약물로 효과가 없거나 합병증이 발생한 경우에는 수술적 치료가 필요할 수 있으며, 대표적으로는 위식도 괄약근을 강화하는 방식의 수술이 있다. 최근에는 GERD의 진단과 치료에 있어 다양한 기술들이 발전하고 있다. 예를 들어, 최소 침습적인 내시경 기법을 이용한 치료가 점차 보편화되고 있으며, 이는 회복 기간을 단축시키고 합병증의 위험을 줄이는 데 기여하고 있다. 또한, 디지털 헬스케어 기술을 활용한 모니터링 시스템이 개발되어 환자의 증상을 실시간으로 추적하고, 필요 시 즉각적인 피드백을 제공하는 방식으로 관리를 용이하게 하고 있다. 위식도 역류증은 현대 사회에서 흔히 발생하는 질환으로, 그 원인은 다양하고 치료 방법도 여러 가지가 있다. 따라서 조기에 정확한 진단을 받고 지속적인 관리와 치료를 통해 증상을 완화하고 합병증을 예방하는 것이 중요하다. |
| ※본 조사보고서 [세계의 위식도 역류증 (GERD) 시장 (2023년~2027년)] (코드 : IRTNTR71291-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 위식도 역류증 (GERD) 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |

